Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex

Free Radical Biology and Medicine

Volumn 47, Issue 10, 2009, Pages 1440-1449

  Clark, Christina B ^a   Rane, Madhavi J ^a,b   El Mehdi, Delphine ^a   Miller, Cynthia J ^a   Sachleben Jr , Leroy R ^a   Gozal, Evelyne ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Free radicals; Geldanamycin; Heat shock protein 90; Protein degradation; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CELL CYCLE PROTEIN 37; GELDANAMYCIN; GLUTATHIONE; HEAT SHOCK PROTEIN 90; MENADIONE; PROTEASOME; PROTEIN KINASE B; RAF PROTEIN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; CELL STRAIN; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; DRUG MECHANISM; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BENZOQUINONES; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; OXIDATIVE STRESS; PC12 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VITAMIN K 3;

EID: 70350227307     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.08.012     Document Type: Article

References (52)

1. Pratt W.B., and Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18 (1997) 306-360
2. Samali A., and Orrenius S. Heat shock proteins: regulators of stress response and apoptosis. Cell Stress Chaperones 3 (1998) 228-236
3. Takayama S., Reed J.C., and Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 22 (2003) 9041-9047
4. Sreedhar A.S., and Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy. A comprehensive review. Pharmacol. Ther. 101 (2004) 227-257
5. Hatakeyama S., Matsumoto M., Yada M., and Nakayama K.I. Interaction of U-box-type ubiquitin-protein ligases (E3s) with molecular chaperones. Genes Cells 9 (2004) 533-548
6. Ellis R.J. Molecular chaperones: plugging the transport gap. Nature 421 (2003) 801-802
7. Csermely P., Schnaider T., Soti C., Prohaszka Z., and Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 79 (1998) 129-168
8. Richter K., and Buchner J. Hsp90: chaperoning signal transduction. J. Cell. Physiol. 188 (2001) 281-290
9. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90 (1997) 65-75
10. Grenert J.P., Johnson B.D., and Toft D.O. The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. J. Biol. Chem. 274 (1999) 17525-17533
11. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., and Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89 (1997) 239-250
12. Zhang H., and Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med 82 (2004) 488-499
13. Basso A.D., S., D. B., Chiosis G., Giri B., Tsichlis P., and Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 277 (2002) 39858-39866
14. Sato S., Fujita N., and Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 97 (2000) 10832-10837
15. Fujita N., Sato S., Ishida A., and Tsuruo T. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem 277 (2002) 10346-10353
16. Grammatikakis N., Lin J.H., Grammatikakis A., Tsichlis P.N., and Cochran B.H. p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Mol. Cell. Biol. 19 (1999) 1661-1672
17. Roe S.M., Ali M.M., Meyer P., Vaughan C.K., Panaretou B., Piper P.W., Prodromou C., and Pearl L.H. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116 (2004) 87-98
18. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., and Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425 (2003) 407-410
19. Graner M.W., and Bigner D.D. Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro-Oncology 7 (2005) 260-278
20. Graner M.W., Cumming R.I., and Bigner D.D. The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. J. Neurosci. 27 (2007) 11214-11227
21. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., Adjei A.A., Sloan J., Atherton P., Vasile V., Salazaar S., Adjei A., Croghan G., and Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol 23 (2005) 1078-1087
22. Grem J.L., Morrison G., Guo X.D., Agnew E., Takimoto C.H., Thomas R., Szabo E., Grochow L., Grollman F., Hamilton J.M., Neckers L., and Wilson R.H. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. 23 (2005) 1885-1893
23. Ramanathan R.K., Egorin M.J., Eiseman J.L., Ramalingam S., Friedland D., Agarwala S.S., Ivy S.P., Potter D.M., Chatta G., Zuhowski E.G., Stoller R.G., Naret C., Guo J., and Belani C.P. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin. Cancer Res 13 (2007) 1769-1774
24. Banerji U., O'Donnell A., Scurr M., Pacey S., Stapleton S., Asad Y., Simmons L., Maloney A., Raynaud F., Campbell M., Walton M., Lakhani S., Kaye S., Workman P., and Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol 23 (2005) 4152-4161
25. Sreedhar A.S., Mihaly K., Pato B., Schnaider T., Stetak A., Kis-Petik K., Fidy J., Simonics T., Maraz A., and Csermely P. Hsp90 inhibition accelerates cell lysis: anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide- and Hsp90-dependent events. J. Biol. Chem. 278 (2003) 35231-35240
26. Dikalov S., Landmesser U., and Harrison D.G. Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling: implications for studies of Hsp90 and endothelial cell nitric-oxide synthase. J. Biol. Chem. 277 (2002) 25480-25485
27. Cysyk R.L., Parker R.J., Barchi Jr. J.J., Steeg P.S., Hartman N.R., and Strong J.M. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem. Res. Toxicol. 19 (2006) 376-381
28. Szabo C., Day J., and Salzman A.L. Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger. FEBS Lett. 381 (1996) 82-86
29. Lamson D.W., and Plaza S.M. The anticancer effects of vitamin K. Altern. Med. Rev. 8 (2003) 303-318
30. Criddle D.N., Gillies S., Baumgartner-Wilson H.K., Jaffar M., Chinje E.C., Passmore S., Chvanov M., Barrow S., Gerasimenko O.V., Tepikin A.V., Sutton R., and Petersen O.H. Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J. Biol. Chem. 281 (2006) 40485-40492
31. Estrela J.M., Ortega A., and Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43 (2006) 143-181
32. McCollum A.K., Teneyck C.J., Sauer B.M., Toft D.O., and Erlichman C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 66 (2006) 10967-10975
33. Nardai G., Sass B., Eber J., Orosz G., and Csermely P. Reactive cysteines of the 90-kDa heat shock protein, Hsp90. Arch. Biochem. Biophys 384 (2000) 59-67
34. Blagosklonny M.V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16 (2002) 455-462
35. Schulte T.W., An W.G., and Neckers L.M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem. Biophys. Res. Commun 239 (1997) 655-659
36. Lerdrup M., Hommelgaard A.M., Grandal M., and van Deurs B. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J. Cell Sci. 119 (2006) 85-95
37. Finn P.F., Mesires N.T., Vine M., and Dice J.F. Effects of small molecules on chaperone-mediated autophagy. Autophagy 1 (2005) 141-145
38. Qing G., Yan P., and Xiao G. Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK). Cell Res. 16 (2006) 895-901
39. Li D. Selective degradation of the IkappaB kinase (IKK) by autophagy. Cell Res. 16 (2006) 855-856
40. Maher P. Proteasome inhibitors prevent oxidative stress-induced nerve cell death by a novel mechanism. Biochem. Pharmacol. 75 (2009) 1994-2006
41. Dice J.F. Chaperone-mediated autophagy. Autophagy 3 (2007) 295-299
42. Kane M.D., Schwarz R.D., St Pierre L., Watson M.D., Emmerling M.R., Boxer P.A., and Walker G.K. Inhibitors of V-type ATPases, bafilomycin A1 and concanamycin A, protect against beta-amyloid-mediated effects on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem 72 (1999) 1939-1947
43. Papathanassiu A.E., MacDonald N.J., Bencsura A., and Vu H.A. F1F0-ATP synthase functions as a co-chaperone of Hsp90-substrate protein complexes. Biochem. Biophys. Res. Commun. 345 (2006) 419-429
44. Nomura M., Nomura N., Newcomb E.W., Lukyanov Y., Tamasdan C., and Zagzag D. Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells. J. Cell. Physiol 201 (2004) 374-384
45. Mikolajczyk M., and Nelson M.A. Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90. Biochem. J 384 (2004) 461-467
46. Wang K.K.W. Calpain and caspase: can you tell the difference?. Trends Neurosci. 23 (2000) 20-26
47. Azuma M., and Shearer T.R. The role of calcium-activated protease calpain in experimental retinal pathology. Surv. Ophthalmol. 53 (2008) 150-163
48. Vanderklish P.W., and Bahr B.A. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int. J. Exp. Pathol. 81 (2000) 323-339
49. Averna M., Stifanese R., De Tullio R., Salamino F., Pontremoli S., and Melloni E. In vivo degradation of nitric oxide synthase (NOS) and heat shock protein 90 (HSP90) by calpain is modulated by the formation of a NOS-HSP90 heterocomplex. FEBS J. 275 (2008) 2501-2511
50. Averna M., Stifanese R., De Tullio R., Salamino F., Bertuccio M., Pontremoli S., and Melloni E. Proteolytic degradation of nitric oxide synthase isoforms by calpain is modulated by the expression levels of HSP90. FEBS J. 274 (2007) 6116-6127
51. Smith I.J., and Dodd S.L. Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt signalling pathway in rat diaphragm muscle. Exp. Physiol. 92 (2007) 561-573
52. Garcia-Morales P., Carrasco-Garcia E., Ruiz-Rico P., Martinez-Mira R., Menendez-Gutierrez M.P., Ferragut J.A., Saceda M., and Martinez-Lacaci I. Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines. Oncogene 26 (2007) 7185-7193